ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results
Research and Markets: Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
These two small-value funds have followed different paths to success in a difficult year for the peer group.